Scinai Immunotherapeutics Ltd. has regained compliance with Nasdaq's minimum bid price rule after its American Depositary Shares closed at or above $1.00 for 19 consecutive business days. This resolves the issue raised in March 2026 when the company's shares had fallen below the $1 threshold for 30 days. Nasdaq confirmed the matter is now closed, allowing Scinai to focus on its biopharmaceutical business and NanoAb program development. The company operates both innovative immunology therapy development and a contract development and manufacturing organization (CDMO).
Scinai Immunotherapeutics Ltd. has regained compliance with Nasdaq's minimum bid price rule after its shares closed at or above $1.00 for 19 consecutive business days. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 21, 2026 17:21 WIB: out of 92 priced US health-sector stocks, 46 rose and 29 fell. Notable movers include Summit Therapeutics Inc (SMMT) at USD 18.61 with a 4.26% gain and a typical hold time of 18 days, AbCellera Biologics Inc (ABCL) at USD 13.07 with a 3.48% gain and a typical hold time of 40 days, and Citius Pharmaceuticals Inc (CTXR) at USD 0.58 with a 3.33% loss and a typical hold time of 16 days.
Jefferies maintains a 'buy' rating on Diageo, forecasting a 35% rise in shares as the company executes a turnaround of its struggling US business, which accounts for 40% of sales. The plan focuses on stabilizing and regaining market share despite a w...
Cryptocurrency markets saw significant gains with Bitcoin rising 5.92% to $85,117 and Ethereum increasing 5.71% to $2,721.85. Other notable increases include Solana up 7.46%, Cardano up 10.55%, and Avalanche up 10.10%. This broad upward movement sugg...
Finbold's AI Agent forecasts a 13% increase in Shiba Inu's price to $0.000006525 by October 1, based on technical indicators and AI models. The prediction uses MACD and RSI signals showing bullish momentum, with two AI models suggesting price targets...
Broadcom (AVGO) is trading at a compelling forward price-to-earnings ratio with strong earnings per share growth expected through fiscal 2028. The company has a solid history of beating earnings expectations, and analyst price targets have risen, cur...
Progressive's reported trailing yield is misleading because it includes a large variable annual dividend paid once a year, in addition to a small regular quarterly dividend. The regular dividend is fixed at $0.40 annually per share, while the variabl...
